Will Abbott Laboratories Beat Analyst Revenue Estimates in Q2?
Abbott Laboratories’ revenue estimates
On July 20, 2017, Abbott Laboratories (ABT) is scheduled to announce its 2Q17 earnings. Wall Street has estimated that the company’s 2Q17 revenue will total ~$6.63 billion, a rise of ~24.3% on a YoY (year-over-year) basis. The company had registered ~$6.3 billion revenues in 1Q17.
Interested in ABT? Don't miss the next report.
Receive e-mail alerts for new research on ABT
The chart above compares analysts’ estimates for Abbott Laboratories and its actual reported revenues in previous quarters. The company exceeded analysts’ estimates in 1Q17.
The company added several products to its portfolio in 2Q17 through continued strategic acquisitions and innovative product launches. The St. Jude acquisition, which Abbott completed in 1Q17, is expected to be a key growth driver for revenue in 2Q17. However, headwinds from China are expected to continue to negatively impact the Nutrition segment’s sales in 2Q17. Freestyle Libre’s continuously increasing demand should add to the diabetes segment revenues. Moreover, the product received reimbursement approval in France in May 2017. For more about the approval, read Abbott’s Freestyle Libre Gets Reimbursement Approval in France. The Established Pharmaceuticals and Diagnostic segments are expected to be the company’s major drivers in terms of 2Q17 sales growth.
Investors seeking diversified exposure to Abbott Laboratories can consider investing in the iShares Core S&P 500 (IVV), which invests ~0.40% of its total holdings in Abbott Laboratories.
Next, let’s look at Abbott Laboratories’ 2Q17 earnings estimates.